The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...